Search
Azficel-T
go.drugbank.com/drugs/DB11051ApprovedWithdrawnAzficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. … Azficel-T is marketed in the US as Laviv for intradermal injection.
Synonyms: Azficel-TPheniprazine
go.drugbank.com/drugs/DB09250ApprovedWithdrawnPheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis. … In addition, it was used for the treatment of other conditions, such as angina pectoris and schizophrenia.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSulfacytine
go.drugbank.com/drugs/DB01298ApprovedBacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. … The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Edoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawnIt was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … [A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113]
Miltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalIt is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. … The CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis.
Epcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigational[L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … [A259736,A258488,A259761,L46516] Epcoritamab promotes the activation and expansion of T-cells and, by being able to bind to both CD20 and CD3, it leads to the T-cell–mediated killing of CD20+ malignant
Categories: Bispecific CD20-directed CD3 T Cell EngagerNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. … By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2.
Enfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalEnfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake … The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseAllogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
go.drugbank.com/drugs/DB16709ApprovedThe product does not remain permanently engrafted, instead being replaced by the patient's own cells over time, which can reduce or even eliminate the need for autografting. … [L35505] It was developed as an alternative to autografting - the process by which a patient's own skin is harvested and grafted onto the burn site - which has the disadvantage of creating a new wound
Ezetimibe
go.drugbank.com/drugs/DB00973ApprovedInvestigational[A15202] By interfering with the intestinal uptake of cholesterol and phytosterols, ezetimibe reduces the delivery of intestinal cholesterol to the liver.[L11347] … [A15202] Ezetimibe is used as an adjunctive therapy to a healthy diet to lower cholesterol levels in primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia